Please login to the form below

Not currently logged in
Email:
Password:

Silence Therapeutics' Ali Mortazavi appointed chairman of ultromics

Takes up the non-executive role at the AI-focused medical imaging firm

Silence Therapeutics' chief executive officer Ali Mortazavi has been appointed non-executive chairman of ultromics - an artificial intelligence-focused medical imaging firm.

Mortazavi has 17 years’ experience in UK companies, particularly in the biotechnology investment field and joined London-based biotech Silence Therapeutics in 2012 leading its refinancing business and driving business.

He said: “I am truly excited to be joining the board of ultromics. Artificial intelligence will increasingly begin to play a bigger role in medicine as well as other sectors. Ultromics plans to use the combination of man plus machine rather than man vs Machine in medical imaging.”

Ultromics - formed in May 2017 - is backed by Oxford Sciences Innovation and the technology has been applied to echocardiograms to improve the diagnostic accuracy of coronary artery disease from 80% to greater than 95%.

25th July 2017

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
Rare thoughts & outcomes - navigating pathways to better outcomes in rare
...
How to pick the perfect training program for your healthcare professionals
You know your team needs training. But not all training providers and programs are created equal. Last week, we shared the benefits of working with specialist learning and development (L&D)...